Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
-
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
-
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
-
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
-
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
-
Moderna's experimental mpox vaccine reduces severity of disease, early study finds
-
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
-
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.45
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,600
Comparables
Valuation
|
Metric
|
EBS
|
MEPW
|
ZUUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.28 | — | — |
Price/Sales | 0.45 | — | — |
Price/Cash Flow | — | 8,783.78 | — |
Price/Earnings
EBS
MEPW
ZUUS
Financial Strength
|
Metric
|
EBS
|
MEPW
|
ZUUS
|
|---|---|---|---|
Quick Ratio | 0.43 | 0.00 | 0.00 |
Current Ratio | 1.06 | 0.00 | 0.01 |
Interest Coverage | −5.47 | — | −4.77 |
Quick Ratio
EBS
MEPW
ZUUS
Profitability
|
Metric
|
EBS
|
MEPW
|
ZUUS
|
|---|---|---|---|
Return on Assets (Normalized) | −16.27% | — | −83.34% |
Return on Equity (Normalized) | −44.71% | — | — |
Return on Invested Capital (Normalized) | −14.80% | — | — |
Return on Assets
EBS
MEPW
ZUUS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Hvyqxhgcq | Tzzx | $86.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Bzhnfbts | Qkhdv | $74.3 Bil | |||
| Haleon PLC ADR
HLN
| Thhmwfs | Xhcyh | $45.9 Bil | |||
| Viatris Inc
VTRS
| Txvlxgyzd | Kpzrh | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Pxvntrn | Nxcmv | $13.2 Bil | |||
| Catalent Inc
CTLT
| Nnxhywlkx | Dbjwqqc | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Fxcmthwml | Lctyl | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Jmfvgfsb | Gkgx | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Yjrvzvrsh | Syfws | $2.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Wbnmrmhs | Thj | $2.2 Bil |
United States